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Identifying mechanisms that underlie the resistance of
human melanoma to radiation and chemotherapy is
expected to assist in developing new strategies for the
treatment of this tumor type. We recently demonstrated
that through up-regulation of TNFa, ATF2 increases the
resistance of late stage melanoma cells to apoptosis
induced by UV-irradiation. In elucidating the role of
ATF2 kinases, we now demonstrate that ASK1/MKK6/
p38 elicits suppression of Fas expression. ASK1/p38
downregulates the expression of a Fas via NF-kB/SP1
site on the Fas promoter. Deletion or mutation of NF-
kB/SP1 within the Fas promoter abrogates p38 eect.
ASK1/p38 silences the Fas promoter by inhibition of
IkBa phosphorylation – thereby limiting NF-kB activity.
Forced expression of a dominant negative form of p38
(p38-ASP) or treatment with p38 pharmacological
inhibitor, SB203580, increases NF-kB activity, Fas
expression and the levels of UVC-induced apoptosis in
late stage melanoma cells. Inhibition of p38 activity also
restored NF-kB activity and Fas expression in early-
phase melanoma cells, suggesting that p38 elicited
suppression of Fas expression is not restricted to late
phase melanoma. Identifying p38-mediated down-regula-
tion of Fas expression illustrates a novel regulatory
pathway by which ASK1/MKK6/p38 alters the degree
and nature of the UV-induced apoptosis of melanoma
cells. Oncogene (2000) 19, 3003 – 3012.
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Introduction
Malignant melanoma, a tumor whose incidence
maintains a constant increase in the last decade,
responds poorly to chemotherapy and irradiation.
The molecular mechanism of melanoma progression
and the regulation of apoptosis remains largely
unknown (Meier et al., 1998). In earlier studies we
demonstrated the role of the transcription factor ATF2
in the radiation resistance of late-stage LU1205 human
melanoma cells (Ronai et al., 1998; Ivanov and Ronai,
1999). Forced expression of an inactive form of ATF2,
in which the amino-terminal transactivation domain
was deleted, reduced radiation resistance and augmen-
ted UV-induced apoptosis through the silencing of TNFa
expression and the increase in the fraction of cells that
underwent UV-induced Fas-mediated apoptosis. Con-
versely, over-expression of full-length ATF2 in the
presence of its upstream kinase p38, increased TNFa
expression and protection of melanoma cells from UV-
irradiation (Ivanov and Ronai, 1999).
ATF2 is activated both by JNK and by p38 stress
kinases, which phosphorylate this transcription factor
on residues 69 and 71 (Minden and Karin, 1997; Ip
and Davis, 1998). Common to regulation by p38 and
JNK, in response to stress and DNA damage, is
activation of the upstream components of kinase
cascades, ASK1 (Chen et al., 1999; Ichijo et al.,
1997) and MEKK1 (Minden and Karin, 1997; Ip and
Davis, 1998), both of which are coordinated by
TRAF2 (Yuasa et al., 1998). TRAF2 is also capable
of eliciting negative regulatory signals as illustrated for
TNFa expression in TRAF2 null cells (Nguyen et al.,
1999), possibly due to the nature of its interaction with
multiple signaling components including NIK, ASK1,
GCK and MEKK1.
Compelling evidence supports both a protective and a
promoting role of p38 in the regulation of cell death,
depending on the cell type and the nature of the stimuli
administered, although the mechanisms underlying these
changes are not well understood (Xia et al., 1995). For
example, p38 elicits a pro-apoptotic signal in response to
UV-B irradiation of human keratinocytes through
upregulation of caspases (Shimizu et al., 1999). This
signal can be attenuated by the PI3K/AKT pathway
(Berra et al., 1998). Along the same line, the anti-
proliferative eect of IL-1 is mediated by p38 in the A375
melanoma cells (Itoh et al., 1999). An example of an anti-
apoptotic eect of p38 is provided by Jurkat cells, where
SB202190, which inhibits p38 and JNK, potentiated Fas
(APO-1)- or UV-induced apoptosis (Nemoto et al.,
1998). Furthermore, protection of cells from TNF-
mediated cytotoxicity requires early activation of p38
(Roulston et al., 1998). Like p38, JNK was shown to
elicit either an anti- or a pro-apoptotic signal, depending
on the type of cells and damage. For example, JNK can
elicit a pro-apoptotic signal via upregulation of Fas
ligand expression (Faris et al., 1998a,b) in response to
various stimuli, including cisplatin (Sanchez-Perez and
Perona, 1999) and UV-irradiation (Chen et al., 1996).
The nature of these opposing signals may relate to
their divergent eects on the same cellular targets. For
example, JNK phosphorylates E2F and thus inhibits its
activity whereas p38 reverses Rb-mediated repression
of E2F1 (Wang et al., 1999). In other cases, stress
kinases activate the same subset of substrates. UV-
irradiation, which eciently induces both JNK and
p38, leads to phosphorylation and transcriptional
activation of pro- and anti-apoptotic components
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including ATF2, c-Myc, Bcl2, c-Jun and p53 (Hsu et
al., 1999; Fuchs et al., 1998; Yamamoto et al., 1999;
Noguchi et al., 1999). Investigation of mechanisms
underlying the regulation of apoptosis has revealed the
role of death receptors, including Fas, TNFR1, DR-3,
TRAIL-R1 and TRAIL-R2, whose activity is selec-
tively initiated upon interaction with their respective
ligands (Ashkenazi and Dixit, 1998; Nagata, 1997).
Through their c-Jun and ATF2 substrates, p38 and
JNK have been implicated in the regulation of major
death-signaling cascades including Fas Ligand (FasL)
transcription (Faris et al., 1998a,b; Kasibhatla et al.,
1998), as in the regulation of TNFa expression
(Minden and Karin, 1997; Rhoades et al., 1992; Tsai
et al., 1996), suggesting that the balance between the
stress kinases and their eectors is the key to
understanding the regulation of the degree and nature
of the apoptotic cascade. Since numerous observations
point to a delicate balance between the stress-signaling
components that are coordinated in a cell-type specific
fashion, we further elucidated the regulation of UV-
induced melanoma apoptosis by stress kinases.
In the present study we show that in melanoma cells
p38 negatively regulates the expression of Fas. We
demonstrate that this negative regulation is mediated
via suppression of NF-kB transcriptional activity by
the ASK1/p38 signaling pathway. The role ASK1/p38
plays in regulating the apoptotic pathway induced by
UV-irradiation in melanoma cells through positive
regulation of TNFa and negative regulation of Fas is
discussed.
Results
MKK6/p38 protects whereas MKK7/JNK promotes cell
death of UV-treated melanoma cells
As a first step in assessing the role of ATF2 kinases in
melanoma resistance to irradiation, we used upstream
components of the JNK and p38 kinases, MKK7 and
MKK6, respectively. Forced expression of these
constructs in the melanoma LU1205 cells led to
ecient phosphorylation of p38 (Figure 1a) and JNK
(not shown) and to a corresponding increase in the
phosphorylation of the respective substrates c-Jun and
ATF2 (not shown). Increase in phosphorylation of c-
Jun and ATF2 is reflected in higher transcriptional
activity directed by the 5xJun2tk-Luc reporter (Figure
1b), which is activated by Jun/ATF2 heterodimers (van
Dam et al., 1998). By contrast, p38-ASP, a dominant
negative form of p38, eciently suppressed UVC-
induced activity of 5xJun2tk-Luc (Figure 1b). Co-
transfection of MKK6-DD, a constitutive active form
of MKK6, with GFP, as marker for transfected cells,
allowed us to monitor the degree of death in the
transfected cells.
Under these conditions, MKK6-DD (compared to
an empty vector) caused a twofold decrease in the
basal level of cell death and more than a 2.5-fold
decrease in UV-treated cells (Figure 1c), suggesting
that MKK6 elicits protection of melanoma cells from
UV-induced death. Indeed, forced expression of the
dominant negative form of p38, p38-ASP led to more
Figure 1 Eects of MKK6/p38 and MKK7/JNK1 signaling on UVC-induced death of LU1205 cells. (a) Western blot analysis of
phospho-p38 levels after transient transfection of MKK6-DD into LU1205 cells. (b) Eect of MKK6-DD and p38-ASP on
5xJun2tk-Luc reporter construct. 56105 cells were transiently transfected with 0.5 mg of reporter construct plus 1.0 mg of MKK6-
DD or p38-ASP in the presence of 0.25 mg of pCMV-b-gal. Twenty-four hours after transfection cells were irradiated with UVC
(60 J/m2). After an additional 18 h, irradiated and untreated cells were analysed for luciferase and b-galactosidase activity. The
normalized ratio of luciferase activity to b-galactosidase is shown. (c and d) UVC-induced death levels of LU1205 cells, which had
been transiently transfected with GFP and MKK6-DD (0.25 and 1 mg, respectively) or GFP and p38-ASP, were determined using
PI staining and flow-cytometric analysis. The ratio of GFP+ PI+ cells to the total number of GFP+ cells indicates cell death levels
for transfected cells
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than a 50% increase in the level of UV-induced cell
death (Figure 1c). In contrast to the eect of MKK6/
p38, MKK7 caused an 80% increase in the degree of
cell death following UV-irradiation, whereas the
dominant negative form of JNK, JNK-APF, abolished
UV-mediated apoptosis (from 11 to 1.5%; Figure 1d).
These observations suggest that whereas MKK6
protects, MKK7 promotes death of UV-treated
melanoma cells. These findings are in line with our
former studies revealing the role of transcriptionally
active ATF2 in protection of melanoma cells from
apoptosis and radiation resistance (Ivanov and Ronai,
1999).
p38-elicited protection from cell death coincides with
decreased Fas expression
To further elucidate the nature of p38-elicited protec-
tion of melanoma cells from cell death, we used the
pharmacological inhibitor of p38 catalytic activity,
SB203580 (Young et al., 1997). Addition of the
inhibitor 1 h before UV-irradiation of LU1205 cells
decreased ATF2 phosphorylation (not shown) and
transcriptional activity mediated by 5xJun2tk-Luc
construct (Figure 2a). Under the same conditions,
inhibition of p38 led to a dose-dependent increase of
up to fourfold in transcriptional activities mediated by
NF-kB, about 3.5-fold in activation of Fas promoter
and fivefold in transcriptional activities mediated by
FasL promoter (Figure 2a). These results suggest that
while suppressing ATF2 activities, inhibition of p38
increases NF-kB activities, Fas and FasL transcription,
before as well as after UV-irradiation.
Similar to the eect of p38-ASP, the pharmacologi-
cal inhibitor of p38 caused a dose-dependent increase
(from 10 to 24%) in the fraction of cells that
underwent apoptosis in response to UV-irradiation
(Figure 2b). Increase in UV-induced apoptosis coin-
cided with an increase in surface Fas expression
(Figure 2c), which is the receptor of the prevailing
apoptotic pathway upon UV-treatment of these
melanoma cells (Ivanov and Ronai, 1999). Surface
expression of Fas, measured by mean fluorescence
intensity (MFI) representative of antigenic density on a
per-cell basis, increased (from 95 to 121 MFI on a log
scale) in SB203580-treated cells before (Figure 2c) and
after (not shown) UV-treatment. These results suggest
that p38 down-regulates Fas expression in a manner
that coincides with protection of these melanoma cells
from UV-induced death.
p38 suppression of Fas expression is mediated via the
NF-kB/SP1 site on the Fas promoter
To further delineate the eect of p38 on Fas expression,
we used nested deletions of the Fas promoter (Chan et
al., 1999). Co-expression of the 71.7 kb Fas promoter-
luciferase with MKK6-DD, a constitutively active form
CBA
Figure 2 Inhibition of p38 activity by SB203580 increased UVC-induced apoptosis of LU1205 cells. (a) SB203580 decreased
5xJun2tk-Luc but increased 2xNF-kB-Luc and the Fas and FasL promoter activity 16 h after UVC irradiation of LU12105 cells.
Transient transfection and luciferase analysis were performed as described in the legend to Figure 1. (b) DNA fragmentation
analysis of LU1205 cells treated with indicated concentrations of SB203580 and irradiated with UVC. Per cent apoptotic cells is
indicated. (c) Eect of SB203580 on surface expression levels of Fas determined by PE-conjugated anti-Fas antibodies analysed by
flow cytometry. Medium fluorescence intensity is indicated
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of p38 upstream kinase, resulted in almost complete
suppression of Fas promoter activity. Conversely,
expression of a dominant negative form of p38 led to
an increased level of Fas-Luc activity (Figure 3a).
MKK6-DD’s ability to down-regulate Fas promoter
activity was also seen with nested deletion of the Fas
promoter (7306), but not with the 7259 or 7240
fragments (Figure 3a). This suggests that a certain degree
of suppression may be mediated through response
elements that are located within the7306/7259 domain
which contain one of the three NF-kB sites within the
Fas promoter (Chan et al., 1999). Forced expression of
dominant negative p38 caused 2 – 3-fold increase in Fas-
mediated transactivation using the 7240 or 7259 Fas-
promoter-derived fragment, yet, a super-induction of
Fas promoter activity was seen only with the 7306
fragment, which resulted in an over ninefold increase in
Fas-Luc activity (Figure 3a). These findings suggest that
the sequence within the 7306 fragment serves as the
primary target for mediating suppression of Fas
promoter activity. The latter domain contained the
NF-kB/SP1 site (Chan et al., 1999), suggesting that
p38-mediated suppression is elicited through one of these
target sequences.
The ability of dominant negative p38 to increase
transactivation mediated by the Fas promoter (Figure
3a) is in agreement with the observation that p38
inhibition by SB203580 increased Fas expression
(Figure 2a,c).
To further elucidate the eect of p38 on NF-kB/SP1
target sequence, we used a reporter construct contain-
ing 6xNF-kB/SP1 sites obtained from Fas promoter
(Chan et al., 1999). Forced expression of p38-ASP
caused a fourfold increase in 6xNF-kB/SP1-Luc
activity, which further increased (eightfold) after UV-
irradiation (Figure 3b). Mutation of the NF-kB/SP1
site of the Fas promoter (Chan et al., 1999)
substantially decreased the promoter activity and
abrogated the eect of p38-ASP (Figure 3c).
Similar to the Fas promoter, the FasL promoter
contained an SP1/NF-kB site, which is crucial for its
activity (McClure et al., 1999; Hsu et al., 1999). Forced
expression of p38-ASP led to a marked increase in
FasL-Luc activity, which was abrogated upon muta-
tion in the SP1/NFAT/NF-kB sites at position 7288/
7267 (Figure 3d) but not in the AP1/CREB site at
position 7336/7330 (not shown). These observations
suggest that p38 elicits suppression of FasL transcrip-
tion through the NFAT/SP1/NF-kB site.
Inhibition of NF-kB down-regulates Fas and FasL
expression and Fas-mediated apoptosis of UV-treated
melanoma cells
To determine the relationship between p38’s ability to
suppress NF-kB to the silencing of Fas expression,
we established LU1205 melanoma cells that stably
express the super-repressor IkBDN (Figure 4a).
Figure 3 Eect of p38 signaling on Fas expression before and after UVC treatment. (a) LU1205 cells were transiently transfected
with the nested deletion constructs (0.5 mg) of the 5’ Fas promoter-Luc in the presence of empty vector pcDNA3 or p38-ASP and
MKK6-DD expression constructs (1 mg) and 0.25 mg of pCMV-b-gal. After an additional 18 h, cells were analysed for luciferase
and b-galactosidase activity. The normalized ratio of luciferase activity to b-galactosidase is shown. (b) 6xNF-kB/SP1-Luc construct,
which contained six repeats of the NF-kB/SP1 site from the Fas promoter, was transiently co-transfected into LU1205 cells together
with empty vector or with MKK6-DD and p38-ASP. (c) 7460 Fas-Luc construct was used with the wild type or mutated NF-kB/
SP1 sites. (d) 7453 FasL-Luc construct (0.5 mg) or its mutated variant was transfected into LU1205 cells together with empty vector
or p38-ASP (1 mg). Analysis of luciferase activity was carried out as indicated above
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Expression of the IkBDN reduced NF-kB (p65 – p50
heterodimer) DNA binding activity as monitored by
gel-shift (Figure 4b) and luciferase assay (Figure 4c).
Inhibition of NF-kB coincided with a 3 – 5-fold
decrease in Fas and FasL promoter activities (Figure
4c), which was also seen at the levels of Fas and
FasL expression (not shown). This finding suggests
that NF-kB positively regulates Fas expression and
further establishes the relationship between NF-kB
and Fas/FasL expression. Antagonistic antibodies to
Fas reduced apoptosis of the parent but not of
IkBDN transfected cells, suggesting that suppression
of Fas expression by IkBDN abolished Fas-mediated
death in response to UV-treatment. Conversely,
pretreatment of IkBDN expressing cells with antag-
onistic mAbs to TNFR1 caused a decrease in the
degree of UV-induced cell death (Figure 4d). Along
the same line, treatment with TNFa and cyclohex-
imide induced apoptosis in the IkBDN cells but not
in the parent LU1205 cultures (Figure 4e). This
observation suggests that attenuating NF-kB activity
sensitized LU1205 cells to TNFa mediated cell death.
Further, antagonistic antibodies to TNFa also elicited
a clear decrease in the level of UV-induced cell death
in IkBDN but not in the parent LU1205 cells (not
shown). These observations suggest that reduced NF-
kB activity aected the death signaling cascade and
point to a delicate balance between TNFR- and Fas-
signaling pathways, which aects the nature and
degree of UV-mediated apoptosis of these melanoma
cells.
ASK1/p38 elicits suppression of Fas expression via
downregulation of NF-kB activities
To further study p38/NF-kB relation to the regulation
of Fas expression, we used the constitutively active
forms of p38 upstream kinases MKK6-DD and
ASK1DN. Forced expression of ASK1DN increased
p38 phosphorylation (Figure 5a) and led to a marked
(13-fold) decrease in NF-kB promoter activities
(Figure 5b). Whereas JNK-APF, a dominant negative
form of JNK, did not block ASK1-mediated inhibi-
tion of NF-kB transcriptional activities, p38-ASP was
capable of attenuating some of this inhibition (from
13 to sixfold).
Similar to ASK1, MKK6-DD was also ecient
in eliciting inhibition of NF-kB activities (4seven-
fold), which were partially attenuated upon co-
expression of p38-ASP (down to fourfold). Forced
expression of p38-ASP eciently increased the level
of NF-kB transcriptional activity (4threefold over
the high basal level in these cells; Figure 5b).
Furthermore, forced expression of ASK1DN caused
Figure 4 Suppression of NF-kB activity by IkBDN confers sensitivity to TNFa-dependent apoptosis. (a) LU1205 cells were stably
transfected with pCMV4-IkBDN plus pcDNA3-neo or with pCMV4 plus pcDNA3-neo constructs (control). Levels of IkB were
detected in nontreated or UVC-treated transfected cells 18 h after treatment by Western blotting with an anti IkB (C-terminal) Ab.
(b) EMSA of nuclear extracts of control and IkBDN-transfected cells 3 h after UVC irradiation (lanes 1 – 4). UVC-treated nuclear
extracts of control (lane 2) and IkBDN-transfected cells (lane 4) were pretreated before EMSA with antibodies against NF-kB p50
or p65 subunits (N-terminal and C-terminal) as indicated. Position of NF-kB DNA-binding complexes is indicated by arrows; ss –
super-shifted and ns – nonspecific bands. (c) The Fas, FasL, and NF-kB promoter activity in control or IkBDN-transfected cells.
(d) Apoptosis analysis of LU1205-neo and LU1205/IkBDN cells in the presence of antagonistic Abs against Fas and TNFR1 was
performed as indicated in Materials and methods. (e) Analysis of apoptosis of LU1205-neo and LU1205/IkBDN cells 30 h after
treatment with TNFa (10 ng/ml) and CHX (10 mg/ml)
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a dose-dependent decrease in promoter activities of
Fas (Figure 5c). Down-regulation of the Fas
promoter could be attenuated upon forced expres-
sion of p38-ASP (Figure 5c), further confirming
that suppression of the Fas promoter by ASK1 is
mediated by p38.
To reveal mechanisms that underlie ASK1/MKK6
inhibition of NF-kB activities, we monitored the level
of IkB phosphorylation, which directly reflects the
availability of active NF-kB. Forced expression of
ASK1DN reduced the level of IkB phosphorylation,
which could be partially restored upon expression of
p38-ASP (data not shown). Similarly, inhibition of
p38 by the pharmacological inhibitor, or treatment
with UV-irradiation, led to a twofold increase in the
phosphorylation of IkB, monitored in solid phase
kinase reaction. A further increase in phosphorylation
of IkB of more than fourfold was observed upon co-
treatment of UV and SB203580 (Figure 5d, upper
panel). Increased IkB phosphorylation inversely
correlated with the level of IkB expression, most
likely due to increased degradation of phosphorylated
IkB (Figure 5d, lower panel).
Low NF-kB activity and poor Fas expression coincides
with high p38 activity in early-stage melanoma WM1552
cells
The relationship demonstrated in our studies for
ASK1/p38 dependent NF-kB activity and Fas/FasL
expression is exemplified in the human melanoma
tumor WM1552-derived cells. This early-phase mela-
noma cell line exhibits low activity of JNK and NF-kB
which were shown to be attributed to poor GCK
expression (Ivanov et al., 2000). The WM1552 cells
possess poor NF-kB and Fas activities as reflected in
the analysis of the respective promoters (not shown).
Corresponding to the low levels of NF-kB and Fas
promoter there is a relatively low expression of Fas cell
surface protein, which is increased upon UV irradiation
and furthermore (39 to 53 MFI) upon treatment with
the pharmacological inhibitor of p38 (Figure 6a).
Similarly, expression of FasL is elevated in cells treated
with the SB203580 inhibitor (Figure 6b). Increase in
Fas and FasL expression coincides with an increased
level of cell death from 20 to 35% in UV-irradiated
and SB203580-treated cells (Figure 6c). Similarly,
Figure 5 Eect of ASK1/p38 signaling on NF-kB and Fas promoter activities. (a) LU1205 cells were transiently transfected with
empty vector pcDNA3 or ASK1DN construct. Western blot analysis was performed for detection of phospho-p38 and p38 levels. (b)
LU1205 cells were transiently transfectd with 2xNF-kB-Luc (0.5 mg) plus ASK1DN (0.3 mg), or MKK6-DD (0.3, 1.0 mg), IkBDN
(0.3 mg), p38-ASP or JNK-APF (1 mg) constructs (control cells were transfected 2xNF-kB plus pcDNA3). Relative luciferase activity
was detected 36 h after transfection. (c) LU1205 cells were transiently transfected with Fas-promoter-Luc constructs (0.5 mg) and
ASK1DN (0.3 or 1 mg as indicated). p38-ASP (1 mg) was transfected alone or in combination with ASK1DN. (d) Solid-phase kinase
assay with GST-IkB as substrate was also performed for control, UVC-treated, SB203580 (5 mM) treated, UVC+SB203580-treated
cells. Relative radioactivity of GST-IkB is indicated. Western blot analysis was performed for detection of total IkBa levels (lower
panel)
Regulation of melanoma apoptosis by p38
VN Ivanov and Z Ronai
3008
Oncogene
forced expression of p38 dominant negative construct
increased level of apoptotic cells from 23 to 35% after
UV-irradiation (Figure 6d). This data provides an
example for a relevant scenario of melanoma cells in
which altered regulation of NF-kB and Fas could be
attributed to p38 and is reflected in the sensitivity of
these melanoma cells to undergo apoptosis in response
to UV-irradiation.
Discussion
Unveiling mechanisms that underlie the resistance of
melanoma to radiation and chemotherapy is important
to the identification of a means to better overcome this
major clinical obstacle. In this study we identify a new
regulatory pathway, which plays a key role in the
regulation of Fas expression. Our data demonstrates
that p38 elicits suppression of Fas expression in human
melanoma cells, which is mediated by its inhibition of
IkB phosphorylation and silencing of NF-kB. Weak
activity of NF-kB and low expression of Fas are found
to be ASK1/p38-dependent since inhibition of p38
activities was sucient to increase NF-kB activity, Fas/
FasL expression and the respective degree of apoptosis
in response to UV-irradiation. Our studies also identify
WM1552 early-phase melanoma cell line where this
mechanism prevails, suggesting that p38-elicited down-
regulation of Fas expression is not restricted to late-
phase melanoma cells. Through its suppression of NF-
kB activity and Fas expression, p38 augments the up-
regulation of TNFa, which is mediated by its ATF2
eector. Given that TNFa and Fas comprise the
balanced regulation of programmed cell death in
human melanoma, up-regulation of TNFa in accor-
dance with down-regulation of Fas, is expected to have
a major impact on melanoma sensitivity to undergo
apoptosis in response to external stimuli. Indeed,
melanoma cells in which the Fas pathway represent
the major death signaling and where TNFa elicits a
survival signal, the combined eects of p38 through
ATF2 and NF-kB is expected to decrease the degree of
damage-induced death and thus confer resistance to
such treatments. Our data directly supports this model
(Figure 7) which suggests that p38 plays a critical role
in regulating melanoma’s resistance to irradiation, and
identifies the mechanism by which p38 mediates this
regulation. Although in the present study we have
Figure 6 Inhibition of p38 activity by SB203580 increased, Fas/FasL expression and levels of UVC-induced apoptosis in early-
phase WM1552 cells. (a) Surface expression of Fas was determined using flow cytometric analysis of cells that were subjected to
UV-irradiation, SB203580 treatment, UV+SB203580 or sham-treated as indicated. (b) Western blot analysis of FasL levels after
indicated treatments of WM1552 cells. (c) Apoptotic levels were determined after indicated treatment of cells with p38 inhibitor
SB203580 using Annexin-V-FITC staining and flow cytometric analysis. (d) Level of apoptosis (DNA fragmentation analysis) in
WM1552 cells that stably express p38-ASP or Neo control constructs was performed before and after treatment with UVC
irradiation
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focused on two melanoma-derived cell lines, represent-
ing early and late phases in melanoma development, it
is expected that p38 suppression of Fas via NF-kB will
be also found in other melanomas as well as in
dierent tumor types.
The finding that p38 can suppress NF-kB is
supported by studies of p38’s role in apoptosis of
hematopoietic cells, in which the ability of the
pharmacological inhibitor of p38 to block p38
mediated protection from apoptosis was associated
with increased NF-kB activity (Birkenkamp et al.,
1999). Compounds that are known to stimulate p38,
including sorbitol or sodium salicylate, eectively
suppressed NF-kB activity, which could be reversed
upon the expression of dominant negative p38
constructs or the addition of pharmacological inhibi-
tors of p38 (Schwenger et al., 1997, 1998). More recent
studies point to the inhibition of IkB phosphorylation
by p38, although the nature of this inhibition is not
known (Alpert et al., 1999). Here we demonstrate that
ASK1, an upstream regulator of the p38 pathway,
mediates ecient suppression of Fas expression via
inhibition of NF-kB activity. Further support for the
relationship between UV-irradiation and NF-kB-de-
pendent apoptosis is provided by finding that UVA-
irradiation decreases NF-kB activity in human kerati-
nocytes (Djavaheri-Mergny et al., 1999), and that
increased apoptosis in skin requires inhibition of NF-
kB activity (Van Hogerlinden et al., 1999).
In addition, the current studies determine that p38 also
silences FasL expression. Suppresion of FasL is
mediated through the SP1/NFAT/NF-kB site. Although
we cannot exclude NFAT phosphorylation as a result of
an indirect eect of p38 activity (Chow et al., 1997), it is
likely that reduced FasL promoter activity is also
mediated via p38-mediated suppression of NF-kB
activity. Coordinated NF-kB-dependent suppression of
Fas and FasL is expected to cause ecient attenuation of
Fas-mediated apoptosis. Indeed, suppression of p38
caused an increase in UV-induced, Fas-mediated,
apoptosis. JNK may attenuate the suppressive eects
of p38, as supported by the finding that JNK positively
contributes to the expression of FasL (Faris et al.,
1998a,b), thereby antagonizing the eect of p38.
Previously reported data from other laboratories –
as well as from ours – points to the role of p38/ATF2
in positively regulating TNFa expression (Ivanov and
Ronai, 1999; Schafer et al., 1999; Cain et al., 1999).
The concordant roles of p38/NF-kB in the regulation
of Fas vs TNF signaling is further illustrated by the
observation that blocking NF-kB shifted UV-induced
apoptosis from the Fas-mediated-cascade to the TNF-
mediated-cascade. Accordingly, through its inhibition
of Fas/FasL and activation of TNF, ASK1/p38 and its
transcription factor eectors emerge as an important
regulator of apoptotic signaling in human melanoma
cells (Figure 7).
Other cellular regulatory pathways contribute to
NF-kB activity, some of which may involve phosphor-
ylation-independent degradation of IkB (Li and Karin,
1998). Among other regulatory cascades is AKT/PKB,
which was implicated in the regulation of IkB
(Romashkova and Makarov, 1999; Ozes et al., 1999).
Analysis of PKB/AKT phosphorylation in the mela-
noma cells studied here did not reveal changes after
UV-treatment. Other IKK regulatory components
include NIK, TRIP or IRAK, which mediate TNF/
TRAF2- or IL1-inducing signals (Maniatis, 1999).
While expected to be cell type dependent, the nature
of converged IkB regulation by multiple signaling
pathways is a subject for intense investigation.
In summary, our findings position p38 as a key
regulator of TNF and Fas/FasL signaling in melanoma
cells. These observations provide new understanding of
the cellular determinants involved in the choice
between TNF- and Fas-mediated cell death, and
identify ASK1/p38 as a key regulatory component in
dictating the nature and degree of UV-irradiation-
induced apoptosis in this tumor type.
Materials and methods
Cell lines
Human melanoma LU1205 cells were maintained in
MCDB153/L 15 medium (4 : 1) supplemented with 5% fetal
bovine serum (FBS), L-glutamine and antibiotics. WM1552
are early-phase melanoma derived cells, which were main-
tained in the same medium supplemented with insulin (5 mg/
ml). LU1205/neo, and LU1205/IkBDN cell lines were
maintained in the same medium supplemented with G418
(200 mg/ml). Cells were grown at 378C with 5% CO2.
Figure 7 Model for the role of p38 in the regulation of
apoptosis to UV-treated melanoma cells. Our previous studies
have demonstrated the changes in TRAF2/GCK expression and
activities during melanoma progression. Through the regulation
of both p38 and JNK signaling TRAF2/GCK and their eectors
p38/JNK kinases and ATF2/c-Jun transcription factors were
implicated in melanoma sensitivity to radiation (Ivanov et al.,
2000; Ivanov and Ronai, 1999; Ronai et al., 1998). Data shown in
the present study identifies another layer of regulation, namely,
the suppression of Fas expression upon p38 activation. This
suppression is mediated via down-regulation of NF-kB activities
that are p38-dependent. According to these observations activated
p38 decreases the phosphorylation of IKK and NF-kB inhibitor.
Whereas the mechanism underlying this decrease is yet to be
elucidated, it results in the inhibition of NF-kB activity. Being
important positive factor in the regulation of Fas and FasL
expression, such suppression yields the decrease in Fas and FasL
expression. In concordant with this suppression the p38 pathway
eectively increases the activity of ATF2 and c-Jun which were
implicated as positive factors in the regulation of TNFa
expression. Given the antiapoptotic role of TNFa and the
proapoptotic signal of Fas the change in Fas vs TNFa expression
results in the increased sensitivity of the melanoma cells to
radiation. It is expected that similar changes would take place in
tumors where Fas and TNFa elicit negative and positive
apoptotic signals, respectively
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Stable transfection and selection
The expression vector pCMV4-IkBDN (Brockman et al.,
1995) plus pcDNA3-neo was also co-transfected by electro-
poration (230 V, 1050 mF) into LU1205 cells as previously
described (Ronai et al., 1998). In parallel, pcDNA3-neo
vector (Invitrogen, Carlsbad, CA, USA) was transfected to
generate control LU1205-neo cells. LU1205/neo and
LU1205/IkBDN cell lines were created as a mixed population
of G418-resistant clones.
Transient transfection and luciferase assay
Transient transfection of dierent reporter constructs (0.25 –
0.5 mg) together with quantities of expression vectors and
pCMV-bgal (0.5 mg) into 56105 LU1205 melanoma cells was
performed using Lipofectamine (Life Technologies-BRL). The
reporter constructs used were: 2xNF-kB-Luc (Zandi et al.,
1997), 5xJun2tk-Luc, 5xTRE-tk-Luc and vector tk-Luc (van
Dam et al., 1998),7615TNF-Luc and736TNF-Luc (Rhoades
et al., 1992),71.3 kb FasL-Luc (Kasibhatla et al., 1998),7453
FasL-Luc,7318 FasL-Luc and their mutated variants (Holtz-
Heppelmann et al., 1998; McClure et al., 1999), the Fas
promoter constructs: 1.7 kb FPR1-Luc, D5, D5.7 D5.8, D6 and
their mutated variants (Chan et al., 1999). The expression
constructs, pcDNA3-FLAG-MKK7b1 (Tournier et al., 1999),
pcDNA3-JNK1-APF (Butterfield et al., 1997) p38-ASP (Enslen
et al., 1998) MKK6-DD (Han et al., 1996), and ASK1DN
(Saitoh et al., 1998) were also used in these experiments.
Luciferase activity was determined using the Luciferase assay
system from Promega (Madison, WI, USA) and normalized
based on b-galactosidase levels in transfected cells.
Transient transfection and GFP assay
Melanoma cells (56105) were transiently co-transfected with
expression vectors together with marker plasmid encoding
Green Fluorescent Protein (pGFP; 1 mg and 0.25 mg,
respectively) using Lipofectamine (Life Technologies-BRL).
Forty hours after transfection, cells were irradiated with
UVC (60 J/m2) and 18 h later were stained with propidium
iodide (PI) and analysed by flow cytometry. The ratio of
GFP+PI+/total GFP+ cells was used to measure levels of cell
death of transfected cells.
Treatment and apoptosis studies
Cells were exposed to UVC at 60 J/m2 as previously
described (2). Cycloheximide (10 mg/ml; Sigma, St. Louis,
MO, USA) SB203580 (1 – 10 mM; Calbiochem, San Diego,
CA, USA) and recombinant TNFa (1 – 10 ng/ml) (Pharmin-
gen, San Diego, CA, USA) were used to treat melanoma
cells. Antagonistic monospecific antibodies against Fas (clone
G254 – 274), against TNFa (clone Mab1 from Pharmingen,
San Diego, CA, USA), and against TNFR1 (clone 16803.1
from R&D Systems, Minneapolis, MN, USA) were added as
indicated at final concentrations of 1 – 5 mg/ml.
Annexin-V-FITC staining in the presence of PI was
performed for detection of apoptosis levels using an
Annexin-V-FITC kit (Pharmingen). Flow-cytometric analysis
was performed on a FACScan or FACS Calibur flow
cytometer (Becton Dickinson) using the Lysis II or CellQuest
program, respectively. DNA fragmentation analysis was
performed as described previously (Nicoletti et al., 1991).
Cells were pelleted and resuspended in 0.5 ml of hypotonic
buer with 0.1% Triton X-100 containing PI (40 mg/ml) and
DNase-free RNase A (1 mg/ml). Cells were incubated at
378C for 30 min and analysed on a flow cytometer (Becton
Dickinson). The percentage of cells to the left of the diploid
G0/1 peak, characteristic of hypodiploid cells that have lost
DNA, was calculated as the percentage of apoptotic cells.
Analysis was performed without light scatter gating. Surface
expression of Fas was determined using anti-Fas-PE Ab
(Pharmingen) and flow-cytometric analysis.
Oligonucleotides and Electrophoretic Mobility Shift Assay
(EMSA)
Double-stranded oligonucleotides used in this study as
specific probes for the transcription factor NF-kB, and the
method used for the EMSA were described previously
(Ivanov et al., 1995). DNA-binding activities were quantified
using the BioRad Molecular Imaging system (model G5-250),
equipped with Molecular Analysis software (BioRad, Her-
cules, CA, USA).
Western blot analysis
Cell lysates (50 – 100 mg protein) were resolved on 10%
SDS–PAGE, transferred to nitrocellulose and processed
according to the standard manual. The polyclonal Abs used
were Phospho-MKK3/6 (Ser 189/207); Phospho-p38 (Thr180/
Tyr182); Phospho-ATF2 (Thr71) from New England Bio-
Labs. Polyclonal anti-IkB (C-terminal) Abs were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Monoclonal anti-FasL Abs were obtained from Transduction
Laboratories (Lexington, KY, USA). The primary Abs were
used at dilutions 1 : 1000 – 1 : 3000. The secondary Abs were
anti-rabbit or anti-mouse IgG conjugated to horseradish
peroxidase (dilution 1 : 5000). Signals were detected using the
ECL system (Amersham, Arlington Heights, IL, USA).
Kinase assay
Protein kinase assays were carried out using fusion proteins,
GST-IkBa, as a substrate as previously described (Adler et al.,
1996). Briefly, the GST-IkBa fusion protein (0.5 mg/assay) was
bound to glutathione-sepharose beads after addition of
melanoma proteins as the source of IKK (10 mg/assay) in the
presence of kinase buer (20 mM HEPES, pH 7.6, 1 mM
EGTA, 1 mM dithiothreitol, 2 mM MgCl2, 2 mM MnCl2,
5 mM NaF, 1 mM NaVO3, 50 mM NaCl) at room temperature
for 15 min. The beads were pelleted and washed extensively
with PBST (150 mM NaCl, 16 mM sodium phosphate, pH 7.5,
1% Triton X-100, 2 mM EDTA, 0.1% b-MeOH, 0.2 mM
phenylmethylsulfonyl fluoride, and 5 mM benzamidine) before
incubation with [g-32P]ATP (50 c.p.m./fmol; Amersham) in the
presence of kinase buer. Following extensive washing, the
phosphorylated GST-IkBa was boiled in SDS sample buer
and the eluted proteins were run on a 15% SDS-polyacrylamide
gel. The gel was dried and phosphorylation of the IkB substrate
was determined by autoradiography, followed by quantifica-
tion with a phosphorimager (BioRad).
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